☆ 4.7 Meeting Abstract

Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover

ANNALS OF ONCOLOGY (2016)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 27, Issue -, Pages -

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdw379.31

Keywords

-

Categories

Oncology

Funding

  1. Merck KGaA

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.